Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
This research study is for people who have primary immunodeficiency diseases (PIDD). These conditions make it harder for your body to fight off infections. The study aims to compare a new medicine, TAK-881, with an existing treatment called HyQvia. Researchers want to find out how the body uses these medicines, how safe they are, and if they help reduce the number of infections you might get. This is a "crossover" study, which means participants might try both treatments at different times. The main goal is to carefully measure how much of the medicine stays in your body and for how long. They will also be looking at how well it prevents infections and if there are any side effects. This information will help doctors understand if TAK-881 could be a good treatment option.
At a glance
What is this study about?
If you have a primary immunodeficiency disease (PIDD), your immune system doesn't work as it should, making you more prone to infections. This study is testing a new treatment called TAK-881 to see if it can help people with PIDD. It's an important step in finding better ways to manage these conditions and improve daily life for those affected.
The study involves comparing TAK-881 with an existing treatment called HyQvia. Both are given as an infusion under the skin. Researchers will be looking at several things: how the body handles the medicine (this is called pharmacokinetics), how safe it is, and if it helps reduce infections. This kind of research is crucial for developing new medicines and making sure they are effective and safe for patients.
This is a specific type of study called a "crossover" study. This means that at different times, participants might receive TAK-881 and then HyQvia, or vice-versa. This allows researchers to compare the medicines within the same person, which can give very clear results about their differences. By taking part, you could contribute valuable information that helps many others with PIDD in the future.
Key takeaways
- The study is investigating a new treatment (TAK-881) for primary immunodeficiency diseases (PIDD).
- It compares TAK-881 to an existing treatment, HyQvia.
- The main goals are to check how the body uses the medicine, its safety, and if it reduces infections.
- Participation involves regular clinic visits and receiving study medication via infusion.
- It's a 'crossover' study, so you might try both treatments at different times.
- Results could help improve future treatments for PIDD.
Who may be eligible?
This study is open to both men and women who are 18 years old or older. You must have a diagnosis of a primary immunodeficiency disease (PIDD) to be considered for this study.
There will be specific health checks and medical history reviews to make sure the study is a good fit for you and that it would be safe for you to take part. For example, the study team will need to confirm your PIDD diagnosis and ensure you meet other very specific health requirements.
If you're interested, the study team will go through all the details with you, answer your questions, and help determine if you meet all the necessary criteria to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a doctor's diagnosis of a primary immunodeficiency disease (PIDD)?
- Are you comfortable with the idea of receiving infusions under your skin?
- Are you able to attend regular clinic visits for assessments and monitoring?
What does participation involve?
If you decide to take part in this study, you will be given study medication, either TAK-881 or HyQvia, as an infusion under your skin. The study is designed as a "crossover" study, meaning you might receive one medication for a period, and then switch to the other. You will have regular visits to the clinic where the study team will monitor your health, check for any infections, and perform various assessments such as blood tests to measure how the medicine is working in your body. They will also ask you about any symptoms you experience. The study will continue for a specific period, which the research team will explain in detail, to fully understand the long-term effects and safety of the treatments.
Potential risks and benefits
Locations (8)
- —UnverifiedSlovakia
- —UnverifiedGreece
- —UnverifiedPoland
- —UnverifiedNetherlands
- —UnverifiedSpain
- —UnverifiedCzechia
- —UnverifiedGermany
- —UnverifiedDenmark
Common questions
What is a primary immunodeficiency disease (PIDD)?
PIDD is a group of conditions where your body's immune system doesn't work properly, making you more susceptible to infections.
What does 'crossover study' mean?
It means you might receive one study medicine for a period, and then switch to the other study medicine later. This helps researchers compare them directly.
Will I know which treatment I'm getting?
Yes, this is an 'open-label' study, which means both you and the study team will know which treatment you are receiving at any given time.
What kind of infusions will I receive?
The treatments are given as an infusion under your skin. The study team will show you how to do this or help you with the process.
What are 'endpoints' in a study?
Endpoints are the specific things researchers measure to see if the treatment is working and safe, like how much medicine is in your body, if infections decrease, or if there are side effects.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.